



Godavari Biorefineries Ltd

Dated: May 26, 2026

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street
Mumbai-400001

Script Symbol: GODAVARIB

Script Code:544279

Dear Sir / Madam,

Sub: INVESTOR PRESENTATION

Dear Sir / Madam,

Pursuant to regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015, please find enclosed herewith the Investor Presentation for the quarter and year ended March 31, 2026


This is for your information and records.

Thanking you,
Yours faithfully

For Godavari Biorefineries Limited

Manoj Jain
Company Secretary & Compliance Officer
Membership No. F-7998



 www.godavaribiorefineries.com



CREATING A BEAUTIFUL WORLD

*With Innovation at the Core,
Unified in Growth, Sustainability & Inclusivity.*



Godavari Biorefineries Limited
Investor Presentation
Q4 & FY26



This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Godavari Biorefineries Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale.

All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.



Samir Somaiya
Chairman & Managing Director



Innovation at the Core

Where high-performance solutions and planetary health thrive together.

Shared Future Growth

Co-creation with farmers and customers to fuel shared prosperity and soil vitality.

Creating Value for All

The investors, customers, farmers, the company & the community thrive together.

Sustainability by Design

Circular systems that keep resources in motion and respect nature.

Everything we do begins with the sun, the soil, and the small farmer.



The Green Opportunity

A world in energy transition is paving the way for exactly what GBL creates - bio-based, reliable solutions.

Geopolitical Volatility



- West Asia crisis continues to constrain fossil fuel supplies paving way for bio-based energy.
- The situation impacts food supplies, cooking, transportation, materials and more.

Green Transition



- Accelerating global shift towards renewable energy and sustainable chemicals.
- Customers are seeking trusted, integrated bio-based supply partners - GBL's core strength.

GBL's Competitive Edge



- Current currency dynamics strengthen GBL's export competitiveness.
- While global energy costs surge, GBL's biomass-based model keeps operations stable and cost-competitive.

Policy Momentum



- Global decarbonisation mandates are creating structural, long-term demand for bio-fuels and green chemicals.
- India's E20+ blending roadmap & E85/E100 draft standards signal strong, policy-backed ethanol demand growth.

Bio-Based Solutions Take Centre Stage

As fossil fuel supply chains face mounting stress, industries are turning to reliable, sustainable alternatives. GBL is positioned at the heart of this shift - from oil to soil.



GBL- The Trusted Supply Partner

- Customers are choosing dependable, integrated bio-based partners over fossil-based suppliers.
- GBL's integrated biorefinery model is precisely what the market now demands.



Bio-Based – More Acceptable

- Improved global adoption of bio-based chemicals is opening new, high-value markets.
- GBL's broad specialty portfolio is well-aligned with this structural demand shift.
- Against high cost import of ethanol our ethanol production for captive consumption is our strength.



Bio vs Fossil - The Gap Is Closing Fast

- Price parity with fossil fuels is within reach, making bio-based the economical choice.
- Strengthening competitiveness of bio-based alternatives.

Fuelling the Future

Beyond E20

Draft Standards Notified



India's policy push to explore fuel blends beyond E20 is unlocking a large, growing domestic ethanol market.



Global supply tightness is making GBL's stable, captive bio-based production and supply reliability, a preferred source for export customers.



GBL's new grain-based distillery (200 KLPD) commissioning by June 2026 adds 60 MnL of capacity, timed perfectly for rising blending demand.



A Year of Decisive Progress



Total Income

₹2,000.2 Crs

reflecting steady growth

Reflecting steady growth momentum

▲ 6.0%
YoY



EBITDA*

₹139.3 Crs

reflecting steady growth

Margins stabilizing at 7.0%

▲ 15.8%
YoY



Reduced Finance Costs

₹49.1 Crs


reflecting steady growth

Down ~32% YoY following ₹240 Crs debt repayment

▼ 31.6%
YoY

Bio-Based Chemicals: Accelerating Shift to Specialties

Portfolio Mix Shift (% of Revenue)




Revenue Increased by **6.6% YoY to ₹ 578 Crs**

Driven by richer product mix and rising specialty chemicals contribution

Ethanol



98 Million Litre Ethanol Equivalent sold in FY26



Revenue grew **12.6% YoY to ₹658.6 Crs**

Strong performance despite industry pricing pressure; B-heavy molasses availability a key advantage

Jivana Consumer Brand



FY26 Revenue
₹129 Crs



3-Year CAGR
44%



Retail Reach
7500+
Stores

Turning global challenges into a catalyst for operational excellence and strategic growth.




*Under Ethanol Blending Programme



Karnataka State Boiler Safety Award

#1 in the Cogen Boiler Category at the Karnataka State Boiler Safety Awards - a testament to our zero-accident safety culture and operational excellence at Sameerwadi plant.



AIDA Sustainability Champion Award 2026

Recognised as Sustainability Champion at AIDA 2026 - industry recognition of GBL's leadership in sustainable and integrated bio-refinery operations.



Siemens TechChamps-IT/OT Integration

Honoured at Hannover Messe for pioneering end-to-end IT/OT digital transformation at Sameerwadi - cementing GBL's position as a future-ready, technology-led biorefinery.

Taking GBL's Bio-Based Story to the World



ChemExpo India- 2026

Showcase of GBL's soil-to-specialty story - bio-based, green chemistry that the world's formulators are now actively seeking.



In-cosmetics Global

Global brands are moving away from petroleum-derived inputs - and choosing GBL as their trusted bio-based supply partner.



Growth Beyond Core Business

Bio-Butanol

Scaling High-Value Green Chemistry through Global Partnerships

- Synthomer partnership expands GBL's bio-based monomer and specialty chemicals portfolio into global markets.
- Catalyxx collaboration strengthens technology readiness, positioning GBL strongly in Bio-Butanol landscape.
- Advances GBL's transition towards sustainable chemicals business model.

DME (Dimethyl Ether)

Turning Carbon Into a Strategic Clean Energy Opportunity

- GBL's DME project in collaboration with ICT to research the conversion of CO₂ & Hydrogen at the pilot plant stage is continuing.
- Opens a future-ready clean energy growth vertical aligned with decarbonization and energy transition trends.
- Reinforces GBL's leadership in climate innovation, circular carbon utilization, and ESG-driven growth.



US Subsidiary

Global out-licensing of novel drugs

- GBL has established its dedicated US subsidiary — Sathgen Therapeutics — focused on global intellectual property creation and licensing opportunities.



Oncology

TNBC Oral Inhibitor CDSCO Filing Targeted: Q2 FY26

- GBL is advancing an oral therapy candidate for Triple-Negative Breast Cancer (TNBC).
- Upcoming CDSCO filing strengthens GBL's positioning in innovative therapeutics and high-value healthcare innovation.




Antiviral

Japanese Patent Secured

- GBL has secured a Japanese patent for its novel antiviral therapy platform.
- The patent strengthens future licensing and commercialization opportunities across Asia-Pacific markets.

Drug Discovery for Triple-Negative Breast Cancer (Promising preclinical efficacy in Tripple Negative Breast Cancer)



There is an unmet need for novel ways of targeting TNBC. We are at the forefront of innovation for cancer medicines.



Soil Health

Restoring organic matter & microbiome health across GBL's farming network.



Farmer Empowerment

Co-creating prosperity with small & marginal farmers through GBL programs.



Regenerative Agriculture

Supplementing & reducing dependence on fossil-based fertilizers.



"Everything we do begins with the sun, the soil, and the small farmer."



Segment Highlights

Q4 FY26 Revenue-Mix (Y-o-Y Basis)



(Consolidated)



■ Sugar & Cogeneration
 ■ Bio-Based Chemicals
 ■ Ethanol
 ■ Unallocated

*Some of the business segments are of seasonal nature and accordingly impact the results in the respective quarters
 Note: Percentages may not total 100% due to rounding differences

(Consolidated)



■ Sugar & Cogeneration
 ■ Bio-Based Chemicals
 ■ Ethanol
 ■ Unallocated

**Some of the business segments are of seasonal nature and accordingly impact the results in the respective quarters
 Note: Percentages may not total 100% due to rounding differences*


(Consolidated)

Revenue (Rs. Crs)


| Q4 FY25 | Q4 FY26 | YoY Growth |
|---------|---------|------------|
| 139.1 | 147.4 | 5.9% |

Accelerating Growth Through Specialty Chemicals


Revenue Break-up



EBITDA (Rs. Crs)



EBITDA Margin



- Emerging geopolitical disruptions impacted specialty chemicals business
- Under the current geopolitical environment, competitiveness improved in the quarter. This reduced the share of bio-based specialty chemicals versus ethyl acetate but supported better margins than earlier in ethyl acetate.


(Consolidated)

Revenue (Rs. Crs)


| FY25 | FY26 | YoY Growth |
|-------|-------|------------|
| 542.2 | 578.0 | 6.6% |

Accelerating Growth Through Specialty Chemicals


Revenue Break-up



EBITDA (Rs. Crs)



EBITDA Margin





Increased focus on high-margin specialty chemicals is expected to drive sustainable growth and strengthen overall profitability

Q4 FY26 Segmental Highlights- Integrated Sugar, Co-gen & Ethanol

(Consolidated)

Integrated Sugar, Co-gen & Ethanol Revenue (Rs. Crs)

| Q4 FY25 | Q4 FY26 | YoY Growth |
|---------|---------|------------|
| 435.9 | 411.4 | (5.6%) |




FY26 Segmental Highlights- Integrated Sugar, Co-gen & Ethanol

(Consolidated)


Integrated Sugar, Co-gen & Ethanol Revenue (Rs. Crs)

| FY25 | FY26 | YoY Growth |
|--------|--------|------------|
| 1307.8 | 1383.2 | 5.8% |

Ethanol Revenue (Rs. Crs)



Sugar & Co-gen Revenue (Rs. Crs)




Q4 & FY26 Segmental Highlights- Integrated Sugar, Co-gen & Ethanol

(Consolidated)

Integrated Sugar, Co-gen & Ethanol EBITDA (Rs. Crs)

| Q4 FY25 | Q4 FY26 | YoY Growth |
|---------|---------|------------|
| 104.0 | 83.9 | (19.3%) |


EBITDA (Rs. Crs)



Integrated Sugar, Co-gen & Ethanol EBITDA (Rs. Crs)

| FY25 | FY26 | YoY Growth |
|------|------|------------|
| 81.6 | 97.4 | 19.3% |

EBITDA (Rs. Crs)



| Particulars (in INR Crs) | Q4 FY26 | Q4 FY25 | Y-o-Y | Q3 FY26 | Q-o-Q | FY26 | FY25 | Y-o-Y |
|--|--------------|--------------|----------------|--------------|---------------|----------------|----------------|--------------|
| Revenue from Operations | 564.1 | 579.5 | (2.7%) | 459.9 | 22.7% | 1,987.9 | 1,870.3 | 6.3% |
| Other Income | 5.9 | 9.3 | | 2.1 | | 12.2 | 16.7 | |
| Total Income | 570.0 | 588.8 | (3.2%) | 461.9 | 23.4% | 2,000.2 | 1,886.9 | 6.0% |
| Cost of Materials Consumed | 681.8 | 575.3 | | 455.6 | | 1,489.1 | 1,242.8 | |
| Purchase of Finished Goods | 6.1 | 4.7 | | 4.9 | | 28.9 | 17.8 | |
| Changes in Inventories of Finished Goods and WIP | (341.6) | (222.5) | | (154.6) | | (91.4) | 124.6 | |
| Gross Profit | 223.7 | 231.2 | (3.2%) | 156.0 | 43.4% | 573.5 | 501.8 | 14.3% |
| GP % | 39.2% | 39.3% | | 33.8% | | 28.7% | 26.6% | |
| Employee Benefits Expense | 36.7 | 34.9 | | 34.8 | | 135.2 | 125.4 | |
| Other Expenses | 94.9 | 74.6 | | 76.1 | | 299.0 | 256.1 | |
| EBITDA* | 92.1 | 121.7 | (24.3%) | 45.1 | 104.1% | 139.3 | 120.3 | 15.8% |
| EBITDA % | 16.2% | 20.7% | | 9.8% | | 7.0% | 6.4% | |
| Depreciation and Amortisation Expense | 13.9 | 12.8 | | 13.6 | | 54.5 | 50.1 | |
| EBIT | 78.2 | 108.8 | (28.1%) | 31.6 | 147.6% | 84.8 | 70.3 | 20.8% |
| Finance Costs | 11.3 | 13.1 | | 10.2 | | 49.1 | 71.8 | |
| Profit before exceptional expense | 66.9 | 95.7 | (30.1%) | 21.4 | 213.0% | 35.7 | (1.5) | |
| Profit before exceptional expense (%) | 11.7% | 16.3% | | 4.6% | | 1.8% | (0.1%) | |
| Exceptional Expenses [^] | (3.4) | 0.0 | | 7.9 | | 31.1 | 0.0 | |
| Profit/(Loss) before tax for the period | 70.3 | 95.7 | (26.6%) | 13.5 | 213.0% | 4.6 | (1.5) | |
| Tax Expense | 17.4 | 23.8 | | 5.2 | | 1.0 | (2.6) | |
| Profit/(Loss) after Tax excl. one time impact of Deferred Tax | 52.9 | 71.9 | (26.5%) | 8.3 | 540.8% | 3.5 | 1.1 | |
| One time impact of Deferred Tax | 0.0 | 0.0 | | 0.0 | | 0.0 | 24.5 | |
| Profit/(Loss) after Tax incl. one time impact of Deferred Tax | 52.9 | 71.9 | (26.5%) | 8.3 | 540.8% | 3.5 | (23.4) | |
| PAT % (incl. one time impact of Deferred Tax) | 9.3% | 12.2% | | 1.8% | | 0.2% | (1.2%) | |


Consolidated Balance Sheet – FY26

| Particulars (in INR Crs) | Mar 26 | Mar 25 |
|--|---------------|----------------|
| ASSETS | | |
| Non-current assets | | |
| (a) Property, plant and equipment | 864.1 | 861.3 |
| (b) Capital Work-in-Progress | 129.3 | 22.2 |
| (c) Right to use Asset | 0.7 | 0.3 |
| (d) Intangible Asset | 1.2 | 0.9 |
| (e) Intangible Assets Under Development | 18.6 | 15.2 |
| (f) Investment accounted for equity method | 0.0 | 0.0 |
| (g) Financial Assets | | |
| (i) Investments | 0.1 | 0.0 |
| (ii) Trade Receivables | 0.5 | 3.1 |
| (iii) Other financial assets | 19.0 | 11.9 |
| (h) Other Non-current assets | 27.3 | 17.1 |
| Total non-current assets | 1060.7 | 931.8 |
| Current assets | | |
| (a) Inventories | 775.8 | 739.7 |
| (b) Financial assets | | |
| (i) Trade Receivables | 113.6 | 138.2 |
| (ii) Cash and Cash Equivalents | 15.3 | 12.3 |
| (iii) Bank balances other than above | 16.9 | 19.1 |
| (iv) Other financial assets | 7.9 | 13.3 |
| (c) Other Current Assets | 62.0 | 100.7 |
| Total current assets | 991.5 | 1,023.3 |
| Total Assets | 2052.3 | 1,955.1 |


| Particulars (in INR Crs) | Mar 26 | Mar 25 |
|--------------------------------------|----------------|----------------|
| EQUITY AND LIABILITIES | | |
| EQUITY | | |
| (i) Equity share capital | 51.2 | 51.2 |
| (ii) Other equity | 737.1 | 730.8 |
| Total Equity | 788.3 | 782.0 |
| LIABILITIES | | |
| Non-current liabilities | | |
| (i) Financial Liabilities | | |
| -Borrowings | 333.3 | 239.7 |
| -Lease Liabilities | 0.5 | 0.2 |
| -Other financial liabilities | 9.5 | 6.0 |
| (ii) Provisions | 3.0 | 3.2 |
| (iii) Deferred tax Liabilities | 42.9 | 43.4 |
| (iv) Other Non-Current Liabilities | 0.4 | 0.4 |
| Total Non-Current Liabilities | 389.6 | 292.9 |
| Current liabilities | | |
| (i) Financial liabilities | | |
| -Borrowings | 196.8 | 249.7 |
| -Lease Liabilities | 0.2 | 0.2 |
| -Trade payables | 569.3 | 530.6 |
| -Other financial liabilities | 36.4 | 35.9 |
| (ii) Other Current Liabilities | 64.6 | 60.7 |
| (iii) Provisions | 7.2 | 3.0 |
| (iv) Current Tax Liabilities (Net) | 0.1 | 0.1 |
| Total Current Liabilities | 874.4 | 880.2 |
| TOTAL EQUITY AND LIABILITIES | 2,052.3 | 1,955.1 |

Consolidated Cash Flow Statement – FY26

| Particulars (in INR Crs) | Mar 26 | Mar 25 |
|---|--------------|--------------|
| Cash Flow from Operating Activities | | |
| Profit before Tax | 4.6 | (1.5) |
| Adjustment for Non-Operating Items | 95.7 | 108.5 |
| Operating Profit before Working Capital Changes | 100.3 | 106.9 |
| Changes in Working Capital | 72.2 | (102.0) |
| Cash Generated from Operations | 172.5 | 4.9 |
| Less: Direct Taxes paid | (1.1) | (5.3) |
| Net Cash from Operating Activities | 171.3 | (0.4) |
| Cash Flow from Investing Activities | (162.6) | (62.3) |
| Cash Flow from Financing Activities | (5.7) | 63.8 |
| Net increase/ (decrease) in Cash & Cash equivalent | 3.0 | 1.1 |
| Cash and cash equivalents at the beginning of the year | 12.3 | 11.1 |
| Cash and cash equivalents at the end of the year | 15.3 | 12.3 |



Current Products



Thank You



Godavari Biorefineries Ltd
CIN: L67120MH1956PLC009707
Name – Mr. Ashish Sinha
Title – AGM- IR & Finance
Email – investorrelations@somaiya.com



Ms. Prachi Ambre
Prachi.ambre@in.mpms.mufg.com

Mr. Irfan Raean
irfan.raean@in.mpms.mufg.com

Meeting Request [Link](#)

Website: <https://in.mpms.mufg.com/>

